Oncology Today—May 11, 2026

This week’s Oncology update highlights regulatory progress, late-stage clinical milestones, access decisions, and oncology platform expansion across solid tumors.

In Today’s Newsletter

Dive deeper

Ask Google AI

Ask ChatGPT

Ask Perplexity

Ask Grok

💊 Tovorafenib Phase 3 FIREFLY-2 completes enrollment [1] [Global • 08 May 2026]

https://servier.mediaroom.com/2026-05-08-Day-One-and-Servier-Complete-Enrollment-in-Pivotal-Phase-3-FIREFLY-2-Trial-of-Tovorafenib-as-a-Front-Line-Treatment-for-Pediatric-Low-Grade-Glioma-pLGG
Context: FIREFLY-2 is a global, randomized, open-label Phase 3 trial in patients aged 6 months to 25 years with RAF-altered pLGG requiring first-line systemic therapy.
Key point: Day One Biopharmaceuticals, now part of Servier, completed enrollment of about 400 patients evaluating tovorafenib versus standard-of-care chemotherapy.
Implication: May influence prescriber choice and payer reviews pending full data.

🫁 Rybrevant gains NICE managed-access recommendation [2] [UK • 08 May 2026]

https://www.jnj.com/innovativemedicine/uk/media-center/press-releases/nice-guidance-rybrevant-nsclc-egfr-exon20-managed-access
Context: NICE Final Draft Guidance covers eligible adults in England and Wales with untreated advanced NSCLC with activating EGFR exon 20 insertion mutations.
Key point: Johnson & Johnson said Rybrevant (amivantamab) plus carboplatin and pemetrexed can be used during a managed access period via the Cancer Drugs Fund.
Implication: May expand screening, initiation, and follow-up at scale.

🧬 IBTROZI sNDA accepted by FDA [3] [US • 06 May 2026]

https://investors.nuvationbio.com/news/news-details/2026/Nuvation-Bio-Announces-FDA-Acceptance-of-Supplemental-New-Drug-Application-for-IBTROZI-taletrectinib-with-Updated-Duration-of-Response-in-Advanced-ROS1-Positive-Non-Small-Cell-Lung-Cancer/default.aspx
Context: The filing includes additional TRUST-I and TRUST-II follow-up for advanced ROS1-positive NSCLC across TKI-naïve and TKI-pretreated settings.
Key point: FDA accepted Nuvation Bio’s sNDA for IBTROZI (taletrectinib) to update efficacy information in the label.
Implication: May influence prescriber choice and payer reviews pending full data.

🛡️ Serplulimab adds two EC-approved indications [4] [EU • 10 May 2026]

https://www.henlius.com/en/NewsDetails-5903-26.html
Context: The approvals are based mainly on Phase 3 ASTRUM-002 in nsqNSCLC and ASTRUM-007 in ESCC.
Key point: The European Commission approved Henlius’ serplulimab (Hetronifly) plus chemotherapy for first-line nsqNSCLC and ESCC settings.
Implication: May influence prescriber choice and payer reviews pending full data.

🧫 DOC1021 receives FDA Fast Track in melanoma [5] [US • 06 May 2026]

https://www.prnewswire.com/news-releases/diakonos-oncology-awarded-fast-track-designation-by-fda-for-doc1021-dubodencel-in-unresectable-or-metastatic-cutaneous-melanoma-302763752.html
Context: DOC1021 is a patient-derived, double-loaded dendritic cell investigational therapy; a Phase 1/2 refractory melanoma study is recruiting.
Key point: FDA granted Diakonos Oncology Fast Track designation for DOC1021 (dubodencel) in unresectable or metastatic cutaneous melanoma.
Implication: Signals pipeline investment and modality expansion.

☢️ Alpha DaRT pivotal cSCC trial completes enrollment [6] [US • 08 May 2026]

https://www.alphatau.com/single-post/alpha-tau-completes-patient-enrollment-in-its-u-s-pivotal-skin-cancer-study-advancing-towards-goal
Context: ReSTART is a prospective, multicenter, single-arm, open-label pivotal study in recurrent cSCC after standard therapy.
Key point: Alpha Tau completed enrollment of 88 patients in the ReSTART pivotal trial of intratumoral Alpha DaRT for recurrent cutaneous squamous cell carcinoma.
Implication: May influence prescriber choice and payer reviews pending full data.

🎟️ BIZENGRI receives FDA national-priority voucher [7] [US • 06 May 2026]

https://www.partnertx.com/partner-therapeutics-announces-receipt-of-fda-commissioners-national-priority-voucher-for-bizengri-zenocutuzumab-zbco-in-nrg1-fusion-positive-cholangiocarcinoma/
Context: Partner Therapeutics submitted an sBLA for adults with advanced, unresectable or metastatic NRG1 fusion-positive cholangiocarcinoma after prior systemic therapy.
Key point: FDA awarded a Commissioner’s National Priority Voucher for BIZENGRI (zenocutuzumab-zbco) in this ultra-rare, molecularly defined cholangiocarcinoma population.
Implication: May expand screening, initiation, and follow-up at scale.

🧬 RZ-001 receives FDA RMAT designation in HCC [8] [US • 08 May 2026]

https://www.prnewswire.com/news-releases/rznomics-announces-us-fda-regenerative-medicine-advanced-therapy-designation-granted-to-rz-001-for-hepatocellular-carcinoma-302766762.html
Context: Rznomics is developing RZ-001 for hepatocellular carcinoma.
Key point: FDA granted Regenerative Medicine Advanced Therapy designation to RZ-001 for hepatocellular carcinoma.
Implication: Signals pipeline investment and modality expansion.

🎯 Ampligen combination reports ovarian cancer ORR [9] [US • 07 May 2026]

https://aimimmuno.com/aim-immunotech-announces-50-objective-response-rate-orr-in-upmc-recurrent-ovarian-cancer-phase-2-clinical-trial-suggesting-breakthrough-combination-potential/
Context: UPMC evaluated Ampligen (rintatolimod), pembrolizumab, and cisplatin in a Phase 2 trial in recurrent ovarian cancer.
Key point: AIM ImmunoTech reported a 50% objective response rate for the combination in the trial.
Implication: May influence prescriber choice and payer reviews pending full data.

💉 Halozyme and GSK partner on subcutaneous oncology formulations [10] [Global • 07 May 2026]

https://www.prnewswire.com/news-releases/halozyme-announces-global-collaboration-and-license-agreement-with-gsk-to-develop-subcutaneous-formulations-of-multiple-promising-oncology-targets-302765632.html
Context: The agreement covers development of subcutaneous formulations of multiple oncology targets using Halozyme’s ENHANZE technology.
Key point: Halozyme and GSK entered a global collaboration and license agreement covering multiple oncology targets.
Implication: Signals pipeline investment and modality expansion.

Why it matters

• Lung cancer remains a major focus, with updates across EGFR exon 20 insertion NSCLC, ROS1-positive NSCLC, and PD-1 combinations in nsqNSCLC.
• Regulatory acceleration is active across oncology, including FDA Fast Track, RMAT, and Commissioner’s National Priority Voucher milestones.
• The week included several modality-expansion signals, spanning RAF inhibition, bispecific antibodies, dendritic cell therapy, intratumoral radiotherapy, RNA-based therapy, and subcutaneous delivery.
• Access and implementation were central themes, with NICE managed access for Rybrevant and Halozyme–GSK work on potentially simpler oncology administration.
• Several updates remain dependent on future data maturation, regulatory review, or reimbursement decisions before practice impact is clear.

📚 View the full Oncology archive on our research hub page